MedTrace Logo

Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO

NCT01959919 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 86

Last updated 2018-09-25

Study results available
· View outcomes & findings →

Summary

This study aims to investigate prospectively throughout a period of 3- 6 months and not to exceed 12 months (according to local therapeutic plans) patients experiences of treatment with Factor VIII in the new device named FuseNGO, a new delivery system for Factor VIII compared to their previous delivery system.

Conditions

Interventions

DEVICE

Refacto FusENGO

Dosage will be chosen by PI based on patient condition.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-27
Primary Completion
2016-12-12
Completion
2016-12-12

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01959919 on ClinicalTrials.gov